PT Kalbe Farma Tbk (FRA:LCLA) Total Receivables: €338 Mil (As of Mar. 2026)


FRA:LCLA PT Kalbe Farma Tbk FRA:LCLA
76 GF Score
Price €0.03
GF Value €0.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PT Kalbe Farma Tbk Total Receivables?

PT Kalbe Farma Tbk FRA:LCLA 76 Total Receivables is €338 Mil as of Mar. 2026. GuruFocus rates FRA:LCLA with a GF Score™ of 76/100 and a GF Value™ of €0.07 (Significantly Undervalued). The stock has 2 warning signs investors should review.

PT Kalbe Farma Tbk's Total Receivables for the quarter that ended in Mar. 2026 was €338 Mil.

PT Kalbe Farma Tbk Total Receivables Related Terms

PT Kalbe Farma Tbk Total Receivables Historical Data

* Premium members only.

The historical data trend for PT Kalbe Farma Tbk's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kalbe Farma Tbk Total Receivables Chart

PT Kalbe Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 218.96 289.44 284.89 298.56 301.40

PT Kalbe Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 349.13 310.57 301.30 301.40 338.07
FRA:LCLA
76GF Score
PT Kalbe Farma Tbk FRA:LCLA
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Kalbe Farma Tbk Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €338 Mil mean?
PT Kalbe Farma Tbk (FRA:LCLA) has a Total Receivables of €338 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on PT Kalbe Farma Tbk and its competitors.
Is PT Kalbe Farma Tbk's Total Receivables too high?
PT Kalbe Farma Tbk's current Total Receivables is €338 Mil. Overall, PT Kalbe Farma Tbk has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Total Receivables compare to LLY and JNJ?
PT Kalbe Farma Tbk's Total Receivables of €338 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on PT Kalbe Farma Tbk and its competitors. PT Kalbe Farma Tbk's current Total Receivables is €338 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 58.6% below its estimated fair value. The current Total Receivables is €338 Mil. PT Kalbe Farma Tbk's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Total Receivables is €338 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued. The current stock price of €0.03 is trading 58.6% below its estimated GF Value™ of €0.07. GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.

Key valuation signals for FRA:LCLA:

  • Total Receivables: €338 Mil
  • GF Value™: €0.07 vs. price of €0.03 (58.6% below fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Kalbe Farma Tbk Business Description

Address Jalan Let. Jend. Suprapto Kav. 4, Gedung KALBE, Cempaka Putih, P.O. Box 3105, Jakarta, IDN, 10510
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
76GF Score

Get the complete analysis for FRA:LCLA

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.07
GF Value